Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply from Authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. Eur Urol 2017;71:4-6: Unsplicing a Conflict.
Steinestel J, Bernemann C, Schrader AJ, Lennerz JK. Steinestel J, et al. Among authors: bernemann c. Eur Urol. 2017 Jan;71(1):6-7. doi: 10.1016/j.eururo.2016.08.071. Epub 2016 Sep 15. Eur Urol. 2017. PMID: 27641787 No abstract available.
Reply to Marcus V. Cronauer, Axel S. Merseburger, and M. Raschid Hoda's Letter to the Editor re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3.
Steinestel J, Bernemann C, Schrader AJ, Lennerz JK. Steinestel J, et al. Among authors: bernemann c. Eur Urol. 2017 Apr;71(4):e107-e108. doi: 10.1016/j.eururo.2016.09.022. Epub 2016 Sep 16. Eur Urol. 2017. PMID: 27647434 No abstract available.
Re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149-56: AR-V7 Testing: What's in it for the Patient?
Steinestel J, Bernemann C, Schrader AJ, Lennerz JK. Steinestel J, et al. Among authors: bernemann c. Eur Urol. 2017 Dec;72(6):e168-e169. doi: 10.1016/j.eururo.2017.06.031. Epub 2017 Jul 5. Eur Urol. 2017. PMID: 28688614 No abstract available.
Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.
Chen X, Bernemann C, Tolkach Y, Heller M, Nientiedt C, Falkenstein M, Herpel E, Jenzer M, Grüllich C, Jäger D, Sültmann H, Duensing A, Perner S, Cronauer MV, Stephan C, Debus J, Schrader AJ, Kristiansen G, Hohenfellner M, Duensing S. Chen X, et al. Among authors: bernemann c. Urol Oncol. 2018 Apr;36(4):161.e19-161.e30. doi: 10.1016/j.urolonc.2017.11.001. Epub 2017 Dec 1. Urol Oncol. 2018. PMID: 29198908
37 results